131 related articles for article (PubMed ID: 30235492)
1. Changes in Serum Immunoglobulin G4 Levels in Patients with Newly Diagnosed Graves' Disease.
Hiratsuka I; Yamada H; Itoh M; Shibata M; Takayanagi T; Makino M; Sugimura Y; Hayakawa N; Hashimoto S; Suzuki A
Exp Clin Endocrinol Diabetes; 2020 Feb; 128(2):119-124. PubMed ID: 30235492
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications.
Takeshima K; Inaba H; Furukawa Y; Nishi M; Yamaoka H; Miyamoto W; Ota T; Doi A; Kawashima H; Ariyasu H; Wakasaki H; Furuta H; Nakao T; Sasaki H; Akamizu T
Thyroid; 2014 Apr; 24(4):736-43. PubMed ID: 24256421
[TBL] [Abstract][Full Text] [Related]
3. Serum immunoglobulin G4 levels and Graves' disease phenotype.
Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
5. Serum Immunoglobulin G4 levels are elevated in patients with Graves' ophthalmopathy.
Bozkirli E; Bakiner OS; Ersozlu Bozkirli ED; Eksi Haydardedeoglu F; Sizmaz S; Torun AI; Ertorer ME
Clin Endocrinol (Oxf); 2015 Dec; 83(6):962-7. PubMed ID: 25400133
[TBL] [Abstract][Full Text] [Related]
6. IgG4 serum levels in Graves' orbitopathy.
Comi S; Lanzolla G; Cosentino G; Maglionico MN; Posarelli C; Menconi F; Santini F; Elisei R; Marinò M
J Endocrinol Invest; 2024 Jul; 47(7):1711-1717. PubMed ID: 38127192
[TBL] [Abstract][Full Text] [Related]
7. IgG4 as a Biomarker in Graves' Orbitopathy.
Olejarz M; Szczepanek-Parulska E; Dadej D; Sawicka-Gutaj N; Domin R; Ruchała M
Mediators Inflamm; 2021; 2021():5590471. PubMed ID: 34220335
[TBL] [Abstract][Full Text] [Related]
8. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
Antonelli A; Ferrari SM; Corrado A; Ferrannini E; Fallahi P
Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
[TBL] [Abstract][Full Text] [Related]
9. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus Lytic Reactivation Induces IgG4 Production by Host B Lymphocytes in Graves' Disease Patients and Controls: A Subset of Graves' Disease Is an IgG4-Related Disease-Like Condition.
Nagata K; Hara S; Nakayama Y; Higaki K; Sugihara H; Kuwamoto S; Matsushita M; Kato M; Tanio S; Ishiguro K; Hayashi K
Viral Immunol; 2018 Oct; 31(8):540-547. PubMed ID: 30222515
[TBL] [Abstract][Full Text] [Related]
11. [Distribution of IgG subclasses of TgAb and TPOAb in sera from patients with Graves' disease, Graves' disease plus Hashimoto's thyroiditis and Hashimoto's thyrotoxicosis].
Yuan S; Yu N; Gao Y; Huang W; He Y; Dong B; Lu G; Li M; Cai X; Peng D; Wang Y; Li T; Huang Y; Gao Y; Guo X; Shi B
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(2):110-4. PubMed ID: 24721350
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum granulocyte colony-stimulating factor levels in patients with Graves' disease.
Iitaka M; Noh JY; Kitahama S; Fukasawa N; Miura S; Kawakami Y; Kawasaki S; Yamanaka K; Ishii J; Katayama S; Ito K
Clin Endocrinol (Oxf); 1998 Mar; 48(3):275-80. PubMed ID: 9578815
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
14. Elevated CD69 expression on naive peripheral blood T-cells in hyperthyroid Graves' disease and autoimmune thyroiditis: discordant effect of methimazole on HLA-DR and CD69.
Gessl A; Waldhäusl W
Clin Immunol Immunopathol; 1998 May; 87(2):168-75. PubMed ID: 9614932
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antithyroid drugs efficacy on P wave changes in patients with Graves' disease.
Berker D; Işik S; Canbay A; Aydin Y; Tütüncü Y; Delibaşi T; Güler S
Anadolu Kardiyol Derg; 2009 Aug; 9(4):298-303. PubMed ID: 19666432
[TBL] [Abstract][Full Text] [Related]
16. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
17. Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves' disease.
Akuzawa M; Murakami M; Yamada M; Satoh T; Shimizu H; Mori M
Eur J Endocrinol; 1998 Mar; 138(3):281-5. PubMed ID: 9539302
[TBL] [Abstract][Full Text] [Related]
18. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
Kallner G; Vitols S; Ljunggren JG
J Intern Med; 1996 Jun; 239(6):525-9. PubMed ID: 8656146
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
20. Response to methimazole in Graves' disease. The European Multicenter Study Group.
Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
